

# Medical Preferred Drug List (Medicaid) – July 2025

## Prepared for Nebraska

Drug Class	Non-Preferred Product(s)	Preferred Product(s)
Autoimmune – Infliximab/Remicade	Remicade (infliximab) Infliximab Renflexis (infliximab- abda) Zymfentra (infliximab-dyyb)	Avsola (infliximab- axxq) Inflectra (infliximab-dyyb)
Antiviral-MAB-RSV	Synagis® (palivizumab)	Beyfortus® (nirsevimab-alip)
Heme, IV Iron	Feraheme (ferumoxytol) Ferumoxytol (generic) Injectafer (ferric carboxymaltose) Monoferic (ferric derisomaltose)	Ferrlecit (sodium ferric gluconate) Infed (Iron dextran) Venofer (iron sucrose)
Osteoarthritis, Viscosupplements	Gelsyn-3® (sodium hyaluronate) GenVisc® 850 (sodium hyaluronate) Hyalgan® (1% sodium hyaluronate) Hymovis (sodium hyaluronate) Orthovisc® (1% sodium hyaluronate) Supartz® FX (1% sodium hyaluronate) SynoJoynt® (1% sodium hyaluronate) Synvisc® (hylan (Avian) 8 mg/mL) Triluron® (sodium hyaluronate) TriVisc® (sodium hyaluronate) Visco-3® (1% sodium hyaluronate)	Euflexxa® (1% sodium hyaluronate)
*Oncology	Alymsys (bevacizumab-maly) **Avastin® (bevacizumab) Vegzelma (bevacizumab- adcd)	Mvasi™ (bevacizumab-awwb) Zirabev® (bevacizumab-bvzr)
	Herceptin® (trastuzumab) Herceptin Hycelta™ (trastuzumab and hyaluronidase-oysk) Hercessi (trastuzumab-strf) Herzuma® (trastuzumab- pkrb) Ogivri™	Kanjinti™ (trastuzumab-anns)

\*In specific states Evolent's preferred drug list will apply prior to Molina's. See [New Century Health's Website](#) for the Evolent ODL (oncology drug list). Non-preferred product(s) are only available if process exception criteria are met. This list indicates the common uses for which the drug is prescribed. \*\*Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Molina Healthcare, Inc. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.

	(trastuzumab-dkst) Ontruzant <sup>®</sup> (trastuzumab- dttb) Trazimera <sup>™</sup> (trastuzumab-qyyp)	
*Rituximab	Rituxan <sup>®</sup> (rituximab) Rituxan Hycela <sup>®</sup> (rituximab- hyaluronidase) Riabni <sup>™</sup> (rituximab- arrx) Truxima <sup>®</sup> (rituximab- abbs)	Ruxience <sup>®</sup> (rituximab-pvvr)
Retinal Disorders (Eye)	Eylea <sup>®</sup> (aflibercept) Pavblu <sup>®</sup> (aflibercept) Enzeevu <sup>®</sup> (aflibercept ) Ahzantive <sup>®</sup> (afliberce pt) Opuviz <sup>®</sup> (aflibercept) Lucentis <sup>®</sup> (ranibizum ab)	**Avastin <sup>®</sup> (bevacizumab)
<b>Drug Class</b>	<b>Non-Preferred Product(s)</b>	<b>Preferred Product(s)</b>
	Byooviz <sup>®</sup> (ranibizumab) Cimerli <sup>®</sup> (ranibizumab- eqm) Beovu <sup>®</sup> (brolucizumab-dbll) Macugen (pegaptanib) Susvimo <sup>™</sup> (ranibizumab) Vabysmo <sup>™</sup> (faricimab-svoa) Visudyne <sup>®</sup> (verteporfin)	

\*In specific states Evolent's preferred drug list will apply prior to Molina's. See [New Century Health's Website](#) for the Evolent ODL (oncology drug list). Non-preferred product(s) are only available if process exception criteria are met. This list indicates the common uses for which the drug is prescribed. \*\*Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Molina Healthcare, Inc. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.

